PHSA 19229 Erythropoietin Stimulating Agents - Darbepoetin alfa (Aranesp)
Solicitation number BCPHSA_19229
Publication date
Closing date and time 2026/07/27 17:00 EDT
Description
Notice of Intent to Direct Award
Issued: July 17, 2026
File # PHSA 19229
NOI Title: Erythropoietin Stimulating Agents - Darbepoetin alfa (Aranesp)
Provincial Health Services Authority
Notice is hereby given that Provincial Health Services Authority (“PHSA”) intends to directly award a Contract to the following supplier to provide Erythropoietin Stimulating Agents - Darbepoietin alfa (Aranesp) for a term of five (5) years at an estimated value of $83.6M.
Amgen Canada Inc 6775 Financial Drive, Suite 300 Mississauga, Ontario, Canada
L5N 0A4
In accordance with applicable trade agreements, PHSA has chosen not to proceed with a competitive process for the following reason:• the goods or services can be supplied only by the selected supplier and no alternative or substitute exists for the following reason: (a) due to an absence of competition for technical reasons.
Currently, Erythropoietin Stimulating Agents (ESAs) in British Columbia and Canada are supplied by Amgen Canada Inc. (darbepoetin alfa (Aranesp®)) and Janssen Inc. (epoetin alfa (Eprex®)). Janssen Inc. has announced the discontinuation of Eprex®, effective April 30, 2027. As a result, Aranesp® will become the sole ESA product available in the Canadian market, with no biosimilar alternatives currently approved in Canada.
Vendors who wish to challenge this decision should submit a detailed written objection for the attention of pharmacyteam@phsa.ca before 2:00pm Pacific Time, July 27, 2026. PHSA will review any and all issues received by this date and provide due consideration to each objection.
Please Reference File: PHSA 19229 on all written correspondence.
Provincial Health Services Authority
1795 Willingdon Avenue
Burnaby, BC V5C 6E3
Email: pharmacyteam@phsa.ca Web: www.phsa.ca
Issued: July 17, 2026
File # PHSA 19229
NOI Title: Erythropoietin Stimulating Agents - Darbepoetin alfa (Aranesp)
Provincial Health Services Authority
Notice is hereby given that Provincial Health Services Authority (“PHSA”) intends to directly award a Contract to the following supplier to provide Erythropoietin Stimulating Agents - Darbepoietin alfa (Aranesp) for a term of five (5) years at an estimated value of $83.6M.
Amgen Canada Inc 6775 Financial Drive, Suite 300 Mississauga, Ontario, Canada
L5N 0A4
In accordance with applicable trade agreements, PHSA has chosen not to proceed with a competitive process for the following reason:• the goods or services can be supplied only by the selected supplier and no alternative or substitute exists for the following reason: (a) due to an absence of competition for technical reasons.
Currently, Erythropoietin Stimulating Agents (ESAs) in British Columbia and Canada are supplied by Amgen Canada Inc. (darbepoetin alfa (Aranesp®)) and Janssen Inc. (epoetin alfa (Eprex®)). Janssen Inc. has announced the discontinuation of Eprex®, effective April 30, 2027. As a result, Aranesp® will become the sole ESA product available in the Canadian market, with no biosimilar alternatives currently approved in Canada.
Vendors who wish to challenge this decision should submit a detailed written objection for the attention of pharmacyteam@phsa.ca before 2:00pm Pacific Time, July 27, 2026. PHSA will review any and all issues received by this date and provide due consideration to each objection.
Please Reference File: PHSA 19229 on all written correspondence.
Provincial Health Services Authority
1795 Willingdon Avenue
Burnaby, BC V5C 6E3
Email: pharmacyteam@phsa.ca Web: www.phsa.ca
Contract duration
Refer to the description above for full details.
Trade agreements
-
Please refer to tender description or tender documents
Contact information
Contracting organization
- Organization
-
Provincial Health Services Authority (Incl. BCCSS)
- Email
- pharmacyteam@phsa.ca
Bidding details
Full details for this tender opportunity are available on a third-party site
Click on the button below to be directed to this website. Note that on the third-party site you may need an account to view and/or bid on this tender. Information on any fees or additional costs to access the full details is outlined in the Description tab of this tender opportunity.